Skip to main content

Table 1 Patient characteristics comparison between chemotherapy group and ICI plus chemotherapy group

From: Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study

Patient Characteristics

Overall

(N = 155)

Chemo (N = 98)

ICI Plus Chemo (N = 57)

p

Age (median [IQR])

61.00 [52.50, 68.00]

61.00 [51.00, 67.00]

64.00 [56.00, 68.00]

0.062

Age (%)

   

0.335

 < 60y

 ≥ 60y

69 (44.5)

86 (55.5)

47 (48.0)

51 (52.0)

22 (38.6)

35 (61.4)

 

Gender (%)

   

0.591

 Female

 Male

41 (26.5)

114 (73.5)

24 (24.5)

74 (75.5)

17 (29.8)

40 (70.2)

 

Smoking (%)

   

0.109

 Current smoker

45 (29.0)

29 (29.6)

16 (28.1)

 

 Former smoker

 Never smoker

49 (31.6)

61 (39.4)

36 (36.7)

33 (33.7)

13 (22.8)

28 (49.1)

 

Smoking index (%)

   

0.223

 < 400

 ≥ 400

73 (47.1)

82 (52.9)

42 (42.9)

56 (57.1)

31 (54.4)

26 (45.6)

 

ECOG PS (%)

   

0.944

 0–1

 2–4

126 (81.3)

29 (18.7)

79 (80.6)

19 (19.4)

47 (82.5)

10 (17.5)

 

Pathology (%)

   

0.864

 Adenocarcinoma

113 (72.9)

70 (71.4)

43 (75.4)

 

 Other

 Squamous

6 (3.9)

36 (23.2)

4 (4.1)

24 (24.5)

2 (3.5)

12 (21.1)

 

PD-L1 TPS (%)

   

0.026

 < 1%

40 (25.8)

22 (22.4)

18 (31.6)

 

 ≥ 50%

 1–49%

8 (5.2)

21 (13.5)

4 (4.1)

9 (9.2)

4 (7.0)

12 (21.1)

 

 Unknown

86 (55.5)

63 (64.3)

23 (40.4)

 

Stage (%)

   

0.564

 IVA

 IVB

109 (70.3)

46 (29.7)

71 (72.4)

27 (27.6)

38 (66.7)

19 (33.3)

 

Brain metastasis (%)

   

0.45

 No

 Yes

136 (87.7)

19 (12.3)

84 (85.7)

14 (14.3)

52 (91.2)

5 (8.8)

 

Bone metastasis (%)

   

0.764

 No

 Yes

115 (74.2)

40 (25.8)

74 (75.5)

24 (24.5)

41 (71.9)

16 (28.1)

 

Liver metastasis (%)

   

1

 No

 Yes

145 (93.5)

10 (6.5)

92 (93.9)

6 (6.1)

53 (93.0)

4 (7.0)

 

Metastasis

   

0.86

 Multiple organ metastasis

103 (66.5)

64 (65.3)

39 (68.4)

 

 Single organ metastasis

52 (33.5)

34 (34.7)

18 (31.6)

 

NLR

   

0.968

 < 5

 ≥ 5

105 (67.7)

50 (32.3)

67 (68.4)

31 (31.6)

38 (66.7)

19 (33.3)

 

Bevacizumab (%)

 No

 Yes

137 (88.4)

18 (11.6)

80 (81.6)

18 (18.4)

57 (100.0)

0 (0.0)

0.001

Intrathoracic treatment (%)

   

0.812

 No

 Yes

74 (47.7)

81 (52.3)

48 (49.0)

50 (51.0)

26 (45.6)

31 (54.4)

 

Intrathoracic administration (%)

   

0.518

 No

 Yes

125 (80.6)

30 (19.4)

77 (78.6)

21 (21.4)

48 (84.2)

9 (15.8)

 

Pleurodesis success at 3 months (%)

   

0.983

 Fail

32 (20.6)

20 (20.4)

12 (21.1)

 

 Success

118 (76.1)

75 (76.5)

43 (75.4)

 

 Unknown

5 (3.2)

3 (3.1)

2 (3.5)

 
  1. Abbreviations: ICI Immune checkpoint inhibitor, Chemo Chemotherapy, IQR interquartile range, ECOG PS Eastern Cooperative Oncology Group Performance Status, PD-L1 TPS Programmed cell death-Ligand 1 Tumor cell Proportion Score, NLR Neutrophil to Lymphocyte ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us